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  Evidence-based answer
Cryotherapy is better than heat for 
treating acute muscle strain (strength of 
recommendation [SOR]: C, consensus, 
usual practice, and expert opinion). 
Insuffi cient patient-oriented evidence exists 
regarding use of heat to treat acute soft-
tissue injuries. 
❚ Evidence summary
A comprehensive review of the litera-
ture revealed no studies that compare 
heat and cryotherapy to treat acute soft-
tissue injury. Well-designed human trials 
of general management of acute soft-
tissue injury are rare.1 
Cryotherapy has been the recom-
mended initial treatment for muscle 
strain for more than 30 years, based gen-
erally on expert opinion and physiologi-
cal models, not clinical trials.2 Theoreti-
cally, cryotherapy controls hemorrhage 
and tissue edema, whereas heat enhances 
the infl ammatory response.2 
One human RCT and animal 
studies ﬁ nd beneﬁ ts from cold
A 2007 review evaluated 66 publica-
tions and found only 1 randomized con-
trolled trial conducted on humans.3 The 
intervention in this trial involved apply-
ing cold gel 4 times a day for the fi rst 14 
days after the injury. The control group 
received a room-temperature gel appli-
cation; neither group was aware of the 
temperature differential. 
The study found signifi cant reduction 
in pain at rest, pain with movement, and 
functional disability at intervals of 7, 14, 
and 28 days postinjury (P<.001) among 
patients receiving cold-gel applications. 
Patients receiving cold-gel treatment also 
reported increased satisfaction with treat-
ment compared with the controls. At 28 
days, cold-gel treatment patients scored 
71 on a 100-point satisfaction scale com-
pared with 44 for controls (P<.001).3 
Inconclusive results or signifi cant design 
fl aws limited the validity of all other tri-
als cited in this review.3  
Laboratory studies on rats have 
also demonstrated benefi cial effects of 
cryotherapy after simulated soft-tissue 
injuries.4,5 One study cited a signifi cant 
reduction in infl ammatory cells, based 
on histologic examination, in 43 rats be-
tween 6 and 24 hours after trauma.4 A 
second study of 21 rats showed improve-
ment in associated physiological compo-
nents with cryotherapy, but no statisti-
cally signifi cant improvement in edema.5 
How cold is too cold?
Most authorities recommend empiric 
treatment with cryotherapy during the 
acute infl ammatory phase—the fi rst 24 to 
48 hours after injury.6 Although not rigor-
ously studied, some sources recommend 
applying cold to the involved muscle for 
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the fi rst 4 hours after injury at intervals of 
10 to 20 minutes every 30 to 60 minutes.6 
The literature focuses more on the 
optimal temperature for cryotherapy than 
on the duration and frequency of therapy.7 
Temperatures below 15º to 25°C may ac-
tually result in vasodilatation rather than 
vasoconstriction.7
Evidence for heat is limited
A 2006 Cochrane review that addressed 
treatment of lower back muscular strain, 
not soft-tissue injuries in general, found 
moderate evidence that heat therapy re-
duces pain by 17% and disability in the 
acute setting (P=.001).8 The review also 
cited 2 head-to-head trials that compared 
heat and cryotherapy; however, the study 
designs were poor and the results were 
contradictory.8
Recommendations
Authoritative textbooks consistently 
recommend applying ice for initial treat-
ment of musculoskeletal and soft-tissue 
strains.9 ■
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NSAIDs, Aspirin, and Warfarin)- Serotonin release by platelets plays an important role in hemostasis.
Epidemiological studies of case-control and cohort design have demonstrated an association between use of
psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.
These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.
Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs and SNRIs are
coadministered with warfarin. Patients receiving warfarin therapy should be carefully monitored when Pristiq is
initiated or discontinued. Ethanol- A clinical study has shown that desvenlafaxine does not increase the
impairment of mental and motor skills caused by ethanol. However, as with all CNS-active drugs, patients
should be advised to avoid alcohol consumption while taking Pristiq. Potential for Other Drugs to Affect
Desvenlafaxine-Inhibitors of CYP3A4 (ketoconazole)- CYP3A4 is a minor pathway for the metabolism of Pristiq.
Concomitant use of Pristiq with potent inhibitors of CYP3A4 may result in higher concentrations of Pristiq.
Inhibitors of other CYP enzymes- Based on in vitro data, drugs that inhibit CYP isozymes 1A1, 1A2, 2A6, 2D6,
2C8, 2C9, 2C19, and 2E1 are not expected to have significant impact on the pharmacokinetic profile of Pristiq.
Potential for Desvenlafaxine to Affect Other Drugs- Drugs metabolized by CYP2D6 (desipramine)- In vitro
studies showed minimal inhibitory effect of desvenlafaxine on CYP2D6. Clinical studies have shown that
desvenlafaxine does not have a clinically relevant effect on CYP2D6 metabolism at the dose of 100 mg daily.
Concomitant use of desvenlafaxine with a drug metabolized by CYP2D6 can result in higher concentrations of
that drug. Drugs metabolized by CYP3A4 (midazolam)- In vitro, desvenlafaxine does not inhibit or induce the CYP3A4
isozyme. Concomitant use of Pristiq with a drug metabolized by CYP3A4 can result in lower exposures to that
drug. Drugs metabolized by CYP1A2, 2A6, 2C8, 2C9 and 2C19- In vitro, desvenlafaxine does not inhibit CYP1A2,
2A6, 2C8, 2C9, and 2C19 isozymes and would not be expected to affect the pharmacokinetics of drugs that are
metabolized by these CYP isozymes. P-glycoprotein Transporter- In vitro, desvenlafaxine is not a substrate or
an inhibitor for the P-glycoprotein transporter. The pharmacokinetics of Pristiq are unlikely to be affected by
drugs that inhibit the P-glycoprotein transporter, and desvenlafaxine is not likely to affect the pharmacokinetics
of drugs that are substrates of the P-glycoprotein transporter. Electroconvulsive Therapy-There are no clinical
data establishing the risks and/or benefits of electroconvulsive therapy combined with Pristiq treatment. USE
IN SPECIFIC POPULATIONS: Pregnancy- Patients should be advised to notify their physician if they become
pregnant or intend to become pregnant during therapy. Teratogenic effects – Pregnancy Category C- There are
no adequate and well-controlled studies of Pristiq in pregnant women. Therefore, Pristiq should be used during
pregnancy only if the potential benefits justify the potential risks. Non-teratogenic effects- Neonates exposed
to SNRIs (Serotonin and Norepinephrine Reuptake Inhibitors), or SSRIs (Selective Serotonin Reuptake Inhibitors),
late in the third trimester have developed complications requiring prolonged hospitalization, respiratory
support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings
have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty,
vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness, irritability, and constant crying.
These features are consistent with either a direct toxic effect of SSRIs and SNRIs or, possibly, a drug
discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with
serotonin syndrome [see Warnings and Precautions (5.2)]. When treating a pregnant woman with Pristiq during
the third trimester, the physician should carefully consider the potential risks and benefits of treatment [see
Dosage and Administration (2.2)]. Labor and Delivery- The effect of Pristiq on labor and delivery in humans is
unknown. Pristiq should be used during labor and delivery only if the potential benefits justify the potential risks.
Nursing Mothers- Desvenlafaxine (O-desmethylvenlafaxine) is excreted in human milk. Because of the potential
for serious adverse reactions in nursing infants from Pristiq, a decision should be made whether or not to
discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Only
administer Pristiq to breastfeeding women if the expected benefits outweigh any possible risk. Pediatric Use-
Safety and effectiveness in the pediatric population have not been established [see Box Warning and Warnings and
Precautions (5.1)]. Anyone considering the use of Pristiq in a child or adolescent must balance the potential risks
with the clinical need. Geriatric Use-Of the 3,292 patients in clinical studies with Pristiq, 5% were 65 years of age
or older. No overall differences in safety or efficacy were observed between these patients and younger patients,
but greater sensitivity of some older individuals cannot be ruled out. For elderly patients, possible reduced renal
clearance of desvenlafaxine should be considered when determining dose [see Dosage and Administration (2.2) and
Clinical Pharmacology (12.6) in the full prescribing information]. Renal Impairment- In subjects with renal
impairment the clearance of Pristiq was decreased. In subjects with severe renal impairment (24-hr CrCl < 30
mL/min) and end-stage renal disease, elimination half-lives were significantly prolonged, increasing exposures to
Pristiq; therefore, dosage adjustment is recommended in these patients [see Dosage and Administration (2.2) and
Clinical Pharmacology (12.6) in the full prescribing information]. Hepatic Impairment-The mean t1/2 changed from
approximately 10 hours in healthy subjects and subjects with mild hepatic impairment to 13 and 14 hours in
moderate and severe hepatic impairment, respectively. No adjustment in starting dosage is necessary for patients
with hepatic impairment. 
OVERDOSAGE: Human Experience with Overdosage- There is limited clinical experience with desvenlafaxine
succinate overdosage in humans. In premarketing clinical studies, no cases of fatal acute overdose of
desvenlafaxine were reported. The adverse reactions reported within 5 days of an overdose > 600 mg that were
possibly related to Pristiq included headache, vomiting, agitation, dizziness, nausea, constipation, diarrhea, dry
mouth, paresthesia, and tachycardia. Desvenlafaxine (Pristiq) is the major active metabolite of venlafaxine.
Overdose experience reported with venlafaxine (the parent drug of Pristiq) is presented below; the identical
information can be found in the Overdosage section of the venlafaxine package insert. In postmarketing
experience, overdose with venlafaxine (the parent drug of Pristiq) has occurred predominantly in combination
with alcohol and/or other drugs. The most commonly reported events in overdosage include tachycardia,
changes in level of consciousness (ranging from somnolence to coma), mydriasis, seizures, and vomiting.
Electrocardiogram changes (e.g., prolongation of QT interval, bundle branch block, QRS prolongation), sinus and
ventricular tachycardia, bradycardia, hypotension, rhabdomyolysis, vertigo, liver necrosis, serotonin syndrome,
and death have been reported. Published retrospective studies report that venlafaxine overdosage may be
associated with an increased risk of fatal outcomes compared to that observed with SSRI antidepressant
products, but lower than that for tricyclic antidepressants. Epidemiological studies have shown that
venlafaxine-treated patients have a higher pre-existing burden of suicide risk factors than SSRI-treated
patients. The extent to which the finding of an increased risk of fatal outcomes can be attributed to the toxicity
of venlafaxine in overdosage, as opposed to some characteristic(s) of venlafaxine-treated patients, is not clear.
Prescriptions for Pristiq should be written for the smallest quantity of capsules consistent with good patient
management, in order to reduce the risk of overdose. Management of Overdosage-Treatment should consist
of those general measures employed in the management of overdosage with any SSRI/SNRI. Ensure an
adequate airway, oxygenation, and ventilation. Monitor cardiac rhythm and vital signs. General supportive and
symptomatic measures are also recommended. Gastric lavage with a large-bore orogastric tube with
appropriate airway protection, if needed, may be indicated if performed soon after ingestion or in symptomatic
patients. Activated charcoal should be administered. Induction of emesis is not recommended. Because of the
moderate volume of distribution of this drug, forced diuresis, dialysis, hemoperfusion, and exchange transfusion
are unlikely to be of benefit. No specific antidotes for desvenlafaxine are known. In managing an overdose,
consider the possibility of multiple drug involvement. The physician should consider contacting a poison control
center for additional information on the treatment of any overdose. Telephone numbers for certified poison
control centers are listed in the Physicians Desk Reference (PDR®).
This brief summary is based on Pristiq Prescribing Information W10529C002, revised April 2008.
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